Targeted Protein Degradation
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
64
NCT06927960
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 25, 2025
Completion: Jul 31, 2025
Loading map...